Pear Therapeutics Inc

Pear Therapeutics — Thimble Point Acquisition — SPAC Merger (July 2021)

72 slides from Pear Therapeutics's SPAC merger presentation, Jul 22, 2021

  1. Slide 1: Analyst Day Presentation

    PEAR Prescription Digital Therapeutics Software for the Treatment of Serious Disease Analyst Day Presentation July 22, 2021

  2. Slide 2: Disclaimer

    Disclaimer This presentation is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination (the “Business Combination”) between Thimble Point Acquisition Corporation (“TPAC”) and Pear The

  3. Slide 3: Disclaimer

    Disclaimer This Presentation contains financial forecasts for the Company with respect to certain financial results for the Company’s fiscal years 2020 through 2023. Neither TPAC’s nor Company’s independent auditors have audited, studied, reviewed, compiled or performed any procedures with respect t

  4. Slide 4: Agenda

    Agenda Time Duration Topic Speaker(s) 12:30pm-12:35pm 5 minutes Introductions and Transaction Overview Elon Boms 12:35pm-12:40pm 5 minutes Investment Opportunity Corey McCann The Opportunity for Prescription Digital 12:40pm – 12:45pm 5 minutes Corey McCann Therapeutics (PDTs) 12:45pm – 12:50pm 5 min

  5. Slide 5: The management team

    The MD, PHD JD, MBA MD, MBA MBA MBA CEO CFO & COO CPDO CMO CCO CEO 5

  6. Slide 6: Pear Therapeutics Transaction Overview

    Pear Therapeutics Transaction Overview Pear is preparing to go public through a SPAC merger with Thimble Point Acquisition Corp. and has raised an oversubscribed $125.8 million PIPE to further support long-term growth Pear Therapeutics Pear is the leader in developing prescription digital therapeuti

  7. Slide 7: Pear Therapeutics Investment Highlights

    Pear Therapeutics Investment Highlights Transformational opportunity to disrupt the $3T global healthcare industry with software-based therapeutics that can address unmet medical needs alone and in combination with pharmaceuticals1 Emerging sector of prescription digital therapeutics (PDTs) = softwa

  8. Slide 8: Agenda

    Agenda Introducing Pear Therapeutics Product, Pipeline & Platform Overview Commercial Product Detail Illustrative Pipeline Opportunities Financial Review & Path Forward Appendix 8

  9. Slide 9: Major trends

    Major trends 90% of U.S. $3.8 trillion in annual health care expenditures is for people with chronic converge and mental health conditions1 Number of people who have used telehealth doubled, from 39.4% pre-to highlight to 79.5% post-quarantine2 a need for Across many key disease areas (i.e., substan

  10. Slide 10: Millions of Americans struggle with chronic conditions

    20M Americans 30M Americans 50M Americans ~17M Americans struggle with struggle with chronic struggle with acute and struggle with cancer5 addiction1 insomnia2,3 chronic pain4 Drug treatments are Only 10-20% of Sedatives for short Patients left to choose often discontinued patients receive term use

  11. Slide 11: Prescription Digital Therapeutics are the next modality

    Prescription Digital Therapeutics (PDTs) are 1900+ 1980+ 2000+ 2020+ Small Biologics Cell/Gene Prescription Digital 11 Molecules Therapies Therapeutics

  12. Slide 12: PDTs are poised to disrupt care delivery

    PDTs are poised to Improve reach allowing disrupt care delivery for broader patient impact to Reimbursable events for dashboard interactions in the healthcare system 24/7 remote ac without fear of Favorable side effect profile vs medications Reduce overall healthcare costs Fill gaps in care across l

  13. Slide 13: Agenda

    Agenda The Opportunity For Prescription Digital Therapeutics Product, Pipeline & Platform Overview Commercial Product Detail Illustrative Pipeline Opportunities Financial Review & Path Forward Appendix 13

  14. Slide 14: Pear Therapeutics is the first mover and leader

    Pear Pear is the first mover and 14 product candidates with Therapeutics leader in the space, FDA-authorized products the potential to improve defining the PDT industry reSET, reSET-O, and care across a range of is via the first 3 FDA- Somryst for the treatment therapeutic areas authorized products

  15. Slide 15: Pear's business is enabled by foundational estate

    Pear’s business is enabled by Payor and provider Foundational estate including integration 20+ owned and licensed patents … Products improve over time Pathway requires clinical with more data evidence 15

  16. Slide 16: …and we believe Pear has similarities to

    …and we believe Pear has similarities to 16

  17. Slide 17: Pear's team, culture and investors

    Pear’s team, $250m+ of capital raised culture & investors to date President & CEO represent CFO & COO * Chief Product Development Officer Chief People Officer CMO & Head of Development General Counsel & Secretary person tech + healthcare team in Boston, San Francisco & Raleigh Chief Commercial Offic

  18. Slide 18: Agenda

    Agenda The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Commercial Product Detail Illustrative Pipeline Opportunities Financial Review & Path Forward Appendix 18

  19. Slide 19: Pear has products, pipeline and platform

    Pear has… P R O D U C T S I N P I P E L I N E L E V E R A G I N G P L A T F O R M 19

  20. Slide 20: Pear's first products redefine care

    Pear’s first designed to redefine care for major medical conditions ( U S ) 1 Only product FDA authorized to treat addiction to alcohol, cannabis, cocaine and stimulants Only FDA-authorized software product that’s proven to help patients with opioid use disorder stay in outpatient treatment longer O

  21. Slide 21: Pear's product candidate pipeline

    Discovery POC Pivotal Commercial * Substance Use Disorder Pear has Opioid Use Disorder * Chronic Insomnia a Alcohol Use Disorder Schizophrenia Anxiety (GAD) Depression (MDD) of product Bipolar candidates PTSD Acute and Chronic Pain Migraine Multiple Sclerosis Epilepsy IBS ** Specialty GI *** Oncolog

  22. Slide 22: Our platform enables PDTs at scale

    Our enables the discovery, development, and commercialization of PDTs at scale Component library of therapeutic Clinician dashboard and digital biomarker modalities Patient services center and specialty In-licensing engine to access new pharmacy technologies Data infrastructure and access Remote cli

  23. Slide 23: Agenda

    Agenda The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Product, Pipeline & Platform Overview Illustrative Pipeline Opportunities Financial Review & Path Forward Appendix 23

  24. Slide 24: reSET and reSET-O redefine treatment of SUD and OUD

    and are designed to redefine treatment of Substance Use Disorder (SUD) and Opioid Use Disorder (OUD) + Cognitive Behavioral Therapy (CBT) Real-World Engagement Fluency Training Concept proficiency Contingency Management Cravings & Triggers Craving & Trigger Assessment Urine Drug Screens & Appointmen

  25. Slide 25: reSET product demo

    and product demo Cognitive behavioral Fluency Craving and trigger therapy lessons training Contingency management assessment 25

  26. Slide 26: reSET and reSET-O show strong outcomes

    and show strong and stronger roved abstinence atients abstinent at 12 reSET1 ks5 of patients retained in of patients retained in therapy at 12 therapy for reSET-O2 weeks5 substitution reduction in inpatient hospital for clinician time3 utilization at 6 months6* of continuous reduction in emergency d

  27. Slide 27: Results from the reSET Pivotal Trial

    from the reSET Pivotal Trial * 27 *reSET is indicated for retention in treatment and abstinence.

  28. Slide 28: Results from the reSET-O Pivotal Trial

    from the reSET-O Pivotal Trial * 28 *reSET-O is indicated only for retention in treatment.

  29. Slide 29: Real-world evidence of the product

    of the product in the real world + + 29

  30. Slide 30: reSET-O has published real world outcomes

    has published data on real world outcomes Responder Analysis1 Abstinence in Weeks 9-121* (≧80% negative UDS or self-report) 91% 91% 78% 77% % % tinence, Responders, Abs Pivotal Study RWE Pivotal Study RWE (N = 91) (N = 3,144) (N=91) (n=2,269) Analyses of “Abstinence” for each group: reSET-O® is no

  31. Slide 31: Demonstrated commercial traction

    and have demonstrated commercial traction â‰^ â‰^ *As of 6/1/21, upon the effectiveness of Pear’s contract with Prime Therapeutics LLC, Pear has ~23M covered lives for reSET and reSET-O and has the potential to access up to approximately 20M additional covered lives under the Federal Supply Schedule

  32. Slide 32: Prime Therapeutics: Signed Value Based Contract

    Prime Therapeutics: Signed Value Based Contract Effective 6/1/21 Prime Therapeutics Overview P R I ME Prime Customers T II r RAP r IJT I Sth largest PBM in United States r:t w + {ij BlueCross 30M total covered lives Cap1tal BLUe BlueSh1eld Ewer& BlucCmssBluc hlcld c.t Alnha nn 1 of 6 people covered

  33. Slide 33: Patient and provider testimonials

    and testimonials Heidi Dr. Carolyn Greer, M.D. Samir Mistry, PharmD reSET-O patient Medical Director Vice President of Pharmacy The Bowen Recovery Center PreferredOne Dr. Greer is a paid consultant of Pear Therapeutics, Inc. 33

  34. Slide 34: Somryst for chronic insomnia

    : for 30 million Americans with chronic insomnia FDA-authorized to treat patients with chronic insomnia Examined in 29 completed or ongoing studies Delivers drug-free treatment without the risk of dependence and inappropriate long-term use Addresses supply-demand mismatch in insomnia care ( 300 CBT-

  35. Slide 35: Somryst therapy components

    Cognitive Sleep Restriction & Consolidation Stimulus Control Restructuring 35

  36. Slide 36: Somryst data

    data show rease in the severity of insomnia symptoms1 rease in depression ymptoms2 rease in anxiety in insomnia and ymptoms2 Durable effect on insomnia, depression endpoints epression, and anxiety3-4 Decrease in the severity of insomnia symptoms5 Decrease in the time to sleep onset6 Decrease in unde

  37. Slide 37: Outcomes from the Somryst pivotal trial

    Outcomes from the Somryst pivotal trial IN TWO RANDOMIZED CONTROLLED TRIALS THAT EVALUATED >1400 ADULTS WITH CHRONIC INSOMNIA, SOMRYST USE. RESULTED IN A SIGNIFICANT REDUCTION IN INSOMNIA SEVERITY SYMPTOMS, AND THE REDUCTION WAS MAINTAINED OVER 12 MONTHS." stupy STUDY 2? Mean Insomnia Severity Index

  38. Slide 38: Somryst in the real world

    in the real world Sleep Onset Latency o o o 38

  39. Slide 39: Somryst launch

    launch Pre-Launch Goals Generate Real World Data Gain Early Advocates Test, Learn and Improve: Commercialization & Product Achieve Strategic Payer Coverage Key Initiatives Launch Somryst Leaders Early Experience Program (SL)EEP Direct To Consumer (DTC) awareness & education All-Digital end to end vi

  40. Slide 40: Somryst testimonials

    Wendy Dr. Michelle Primeau, M.D. Renee Wallace, PharmD Somryst patient Medical Director Clinical Account Executive Palo Alto Medical Foundation Serve You Rx Sleep Medicine Center 40 Dr. Primeau is a paid consultant of Pear Therapeutics, Inc.

  41. Slide 41: Agenda

    Agenda The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Product, Pipeline & Platform Overview Commercial Product Detail Financial Review & Path Forward Appendix 41

  42. Slide 42: Illustrative Pipeline Opportunities

    Illustrative Pipeline Opportunities Alcohol Use Disorder Current Stage: Proof of concept Patient Population: Alcohol Use Disorder WW / US Population Size: 100M / 14.5M Studies and Patients: We believe this product candidate is at a stage ready for potential pivotal randomized clinical trial to suppo

  43. Slide 43: Illustrative Pipeline Opportunities

    Illustrative Pipeline Opportunities Schizophrenia Current Stage: Pivotal Patient Population: Psychotic Spectrum Disorders including patients with schizophrenia WW / US Population Size: 25M / 825k Studies and Patients: We believe this product candidate is at a stage ready for potential pre-pivotal st

  44. Slide 44: Agenda

    Agenda The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Product, Pipeline & Platform Overview Commercial Product Detail Illustrative Pipeline Opportunities Appendix 44

  45. Slide 45: S-4 Registration Statement: Operational assumptions underlying projected revenue

    S-4 Registration Statement: Operational assumptions underlying projected revenue Revenue Ramp Pear’s Ability To … The aggregate number of covered lives across Pear’s three FDA-authorized products will increase from approximately 3 million at the … continue to attract new customers and retain existin

  46. Slide 46: S-4 Registration Statement: Annual Historical Financial Results

    S-4 Registration Statement: Annual Historical Financial Results(1) ($ in millions) 2019 2020 Total Early revenue was generated predominately through two collaboration Attractive Market Trends $32.6 $9.4 Revenue agreements with Novartis that were terminated: one commercial and one R&D. Cost of Embedd

  47. Slide 47: Company macro-opportunity

    Company macro-opportunity Growing burden of preventable chronic diseases driving adoption of PDTs Long term effects of pandemic helped accelerate the transition to remote care Pronounced shortage of clinicians Pervasive use of technology by patients and clinicians Abbreviated development timelines w

  48. Slide 48: Covered lives and access

    *Providing access means either listing on formulary, as a covered benefit, purchasing product in bulk, or funding a study. 48 ^ As of 6/1/21, Pear has 23M covered lives for reSET and reSET-O and has the potential to access up to approximately 20M additional covered lives under the Federal Supply Sch

  49. Slide 49: Drivers of commercial product ramp

    Drivers of commercial product ramp Current prescriptions utilized to >20K prescriptions to date in large scalable customers driven by 20 field reps and demonstrate product performance, small marketing budget health economic data, and clinician 2 HEOR pubs and several advocacy letters – more to come

  50. Slide 50: Commercial product ramp through 2023

    Commercial product ramp through 2023 2021 2022 2023 150K—190K Total Rx 12,500 50K—60K Investment in sales, marketing, medical scales relative to covered Nearing steady lives Predominantly Somryst begins to (product mix) state across Prescribing scales as dashboard CPT codes come online reSET and reS

  51. Slide 51: Opportunity for commercial products

    Opportunity for commercial products (varying market penetration) Total Patient Required TAM Required TAM Required TAM US TAM* Population (penetration for $50M (penetration for (penetration for $1B (# of patients) (# of US patients) per product) ** $150M per product) ** per product) ** 20,400,000 2,0

  52. Slide 52: Opportunity for commercial products by scripts per patient

    Opportunity for commercial products (using varying assumptions for script(s) per patient) Billions $12.0 Billions $30.0 $10.0 $25.0 $8.0 $20.0 $6.0 $15.0 $4.0 $10.0 $2.0 $5.0 $0.0 $0.0 0 20% 40% 60% 80% 100% 0 20% 40% 60% 80% 100% TAM Penetration TAM Penetration 52 1 Rx per patient 2 Rx per patient

  53. Slide 53: Commercial flywheel

    Scripts create additional Our commercial patients treated, RWE, and HEOR data points flywheel drives a … Coverage decisions Performance data drive additional drives product prescription growth enhancements Product enhancements support coverage decisions and pricing power 53

  54. Slide 54: Our engine is scalable

    …and our engine is Component library of therapeutics Multi-product clinician dashboards and digital biomarkers Patient services center and specialty pharmacy APIs for academics and partner development Integration into EMRs and practice infrastructures Remote clinical trials infrastructure Claims dat

  55. Slide 55: Pipeline product opportunity

    Pipeline Product Opportunity Alcohol Use Disorder 1,000,000 $3B Schizophrenia 250,000 $750M Anxiety (GAD) 3,000,000 $8B Depression (MDD) 11,000,000 $13B Bipolar 2,300,000 $7B PTSD 6,000,000 $14B 4 product candidates 50,000,000 $70B 4 product candidates 7,750,000 $16B 55

  56. Slide 56: Long-term category leadership

    This Developed by Pear and 3rd parties Mono therapies and drug/software combos as the long-term category Multi-product clinician dashboard leader for Integration into payor and provider networks PDTs Data systems for insight generation 56

  57. Slide 57: Platform effects drive efficiencies

    Platform effects drive increasing efficiencies for our business : : : 57

  58. Slide 58: Pear is the category creator for PDTs

    Pear is the for PDTs Pear is the category creator Pear’s pipeline and platform are poised to PDTs as treatment for most medical conditions and market leader with a drive the space creating a represent a serviceable available market from current serviceable available market from current total address

  59. Slide 59: “’ 1. PEAR ·— } .··- .PEAR -THERAPEUTICS

    “’ 1. PEAR 59 ·— } .··- .PEAR -THERAPEUTICS

  60. Slide 60: Agenda

    Agenda The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Product, Pipeline & Platform Overview Commercial Product Detail Illustrative Pipeline Opportunities Financial Review & Path Forward 60

  61. Slide 61: Upcoming milestones

    Multiple 6-month HEOR data 9, 12-month HEOR data 6-month HEOR Adoption by large healthcare providers Coverage decisions by public and private payors Ex-US expansion* Additional PDT candidates and digital biomarker licenses/acquisitions Clinical data in Alcohol Use Disorder, Depression, Anxiety, Schi

  62. Slide 62: Summary Estimated Sources and Uses

    Summary Estimated Sources and Uses ($ in millions) SPAC Cash in Trust $276.0 Illustrative Price per Share $10.0 Founder Shares(1) 56.3 Pro Forma Shares Outstanding (mm) 165.81 PIPE(2) 125.8 Equity Value 1,658.1 Pear Equity Rollover(3) 1,200.0 (-) Net Cash(4) 456.8 Total Sources $1,658.1 Enterprise V

  63. Slide 63: Category creators offer significant value

    Category creators offer Novel Electric Field-based Leading Chronic Disease Leading Liquid Reimagined Connected Oncology Treatment Management Software Biopsy Diagnostics Dialysis Machines Technology 2015 2016 2017 2018 2019 2020 2017 2018 2019 2020 2016 2017 2018 2019 2020 2018 2019 2020 63 Note: Mar

  64. Slide 64: A compelling moment to join Pear

    This is a compelling moment to join Pear and the $ in millions Pear’s Implied Value at YE ’22 Discounted to Today vs Current Transaction Value 64 Source: Company projections, Company filings, and FactSet as of June 18, 2021. *Disruptive Healthcare Peers include Novocure, Guardant Health, Inspire, Sh

  65. Slide 65: Valuation relative to disruptive healthcare peers

    relative to disruptive healthcare peers Category leaders pioneering approaches to address unmet needs using novel and unique ideology First-mover advantage contributing to acceleration of revenue and profitability momentum 33.07x 17.57x 16.88x 16.69x Discount 15.27x to median * 13.21x 12.47x 9.61x 9

  66. Slide 66: Pear relative to life science comparables

    Pear is to life science comparables Therapeutics targeting psychiatric and neurological diseases 66 pany websites and FactSet as of 06/18/21. * Based on Thimble Point Acquisition Corp.’s valuation of Pear Therapeutics of $1.2bn. ** Pro forma for $144mm follow-on offering in April 2021.

  67. Slide 67: Analogous to biopharma platforms

    analogous to biopharma platforms Pear’s PDT leadership is no less innovative than other biopharma platform companies that brought unorthodox technologies to caregivers, patients and health systems Pioneering developer of Pole position in the development of A sharp departure from prior neuro- First p

  68. Slide 68: First PDTs FDA-authorized to treat addiction

    and First-ever PDT to achieve are the first PDTs FDA medical claims to treat disease FDA-authorized to treat addiction for 21.2M Americans suffering from addiction to alcohol, cannabis, cocaine, and stimulants1 Two successful RCTs in >1,000 SUD patients (alcohol, cannabis, cocaine, stimulants)2-3 Fi

  69. Slide 69: References

    ckfacts/fact/table/US/PST045219 Accessed April 22, 2021.; 4. Atlas on substance use (2010) resources for the prevention and treatment of substance use drsorders. World Health Organization.; https//www.ncbi.nlm.nih.gov/books/NBK553166/ Slide 20 1. TAM = Price x Potential PDT Rx Per Year Sl1de 26 1. C

  70. Slide 70: References

    References 1. Campbell et al., American Journal of Psychiatry. 2014. 171(6):683-690. 2. Yuri A. Maricich, Warren K. Bickel, Lisa A. Marsch, Kirstin Gatchalian, Jeffrey Botbyl & Hilary F. Luderer (2020): Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for trea

  71. Slide 71: References

    References Slide 37 1. Ritterband et al. JAMA Psychiatry. 2017;74(1):68-75. 2. Christensen et al. Lancet Psychiatry. 2016;3(4):333-341. 3. Somryst® Clinician Directions for Use. Boston, MA: Pear Therapeutics, Inc. 2020. Slide 38 1. Thorndike FP et al. Real World Data: Impact of a Digital Therapeutic

  72. Slide 72: Pear Therapeutics

    Pear therapeutics

Thimble Point Acquisition — SPAC Merger (July 2021) on 6ix